JP7520822B2 - ２’－ハロゲン化－４’－チオ－２’－デオキシ－５－アザシチジンアナログおよびその使用 - Google Patents

２’－ハロゲン化－４’－チオ－２’－デオキシ－５－アザシチジンアナログおよびその使用 Download PDF

Info

Publication number
JP7520822B2
JP7520822B2 JP2021516619A JP2021516619A JP7520822B2 JP 7520822 B2 JP7520822 B2 JP 7520822B2 JP 2021516619 A JP2021516619 A JP 2021516619A JP 2021516619 A JP2021516619 A JP 2021516619A JP 7520822 B2 JP7520822 B2 JP 7520822B2
Authority
JP
Japan
Prior art keywords
compound
composition
cancer
subject
aza
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021516619A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022502378A (ja
JPWO2020068657A5 (https=
JP2022502378A5 (https=
Inventor
ジョエル モリス，
ドン ジー． ウィシュカ，
オマー ディエゴ ロペス，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Department of Health and Human Services
Original Assignee
US Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by US Department of Health and Human Services filed Critical US Department of Health and Human Services
Publication of JP2022502378A publication Critical patent/JP2022502378A/ja
Publication of JPWO2020068657A5 publication Critical patent/JPWO2020068657A5/ja
Publication of JP2022502378A5 publication Critical patent/JP2022502378A5/ja
Application granted granted Critical
Publication of JP7520822B2 publication Critical patent/JP7520822B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/12—Triazine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
JP2021516619A 2018-09-25 2019-09-23 ２’－ハロゲン化－４’－チオ－２’－デオキシ－５－アザシチジンアナログおよびその使用 Active JP7520822B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862736246P 2018-09-25 2018-09-25
US62/736,246 2018-09-25
PCT/US2019/052410 WO2020068657A1 (en) 2018-09-25 2019-09-23 2'-halogenated-4'-thio-2'-deoxy-5-azacytidine analogs and use thereof

Publications (4)

Publication Number Publication Date
JP2022502378A JP2022502378A (ja) 2022-01-11
JPWO2020068657A5 JPWO2020068657A5 (https=) 2022-09-08
JP2022502378A5 JP2022502378A5 (https=) 2022-09-08
JP7520822B2 true JP7520822B2 (ja) 2024-07-23

Family

ID=68136598

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021516619A Active JP7520822B2 (ja) 2018-09-25 2019-09-23 ２’－ハロゲン化－４’－チオ－２’－デオキシ－５－アザシチジンアナログおよびその使用

Country Status (7)

Country Link
US (2) US20220033387A1 (https=)
EP (1) EP3856754A1 (https=)
JP (1) JP7520822B2 (https=)
CN (1) CN112888698A (https=)
AU (1) AU2019349424B2 (https=)
CA (1) CA3110224A1 (https=)
WO (1) WO2020068657A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7520822B2 (ja) * 2018-09-25 2024-07-23 ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ ２’－ハロゲン化－４’－チオ－２’－デオキシ－５－アザシチジンアナログおよびその使用
EP4138843A4 (en) * 2020-04-23 2024-07-10 Southern Research Institute COMPOSITION FOR THE TREATMENT OF BLOOD CANCER USING 4'-THIO-5-AZA-2'-DEOXYCYTIDINE AND USES THEREOF
CN114644668B (zh) * 2020-12-18 2026-04-14 鲁南制药集团股份有限公司 一种合成地西他滨的方法

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008523079A (ja) 2004-12-10 2008-07-03 スーパージェン インコーポレイテッド シチジンアナログ及びシチジン誘導体の医薬配合物
WO2011074484A1 (en) 2009-12-18 2011-06-23 Libramedicina, Inc. PROCESS FOR PREPARING SUBSTITUTED 1-O-ACYL-2-DEOXY-2-FLUORO-4-THIO-β-D-ARABINOFURANOSES
WO2013146833A1 (ja) 2012-03-28 2013-10-03 富士フイルム株式会社 １－（２－デオキシ－２－フルオロ－４－チオ－β－Ｄ－アラビノフラノシル）シトシンの塩
WO2014027658A1 (ja) 2012-08-13 2014-02-20 富士フイルム株式会社 １－（２－デオキシ－２－フルオロ－４－チオ－β－Ｄ－アラビノフラノシル）シトシンの合成中間体およびチオヌクレオシドの合成中間体ならびにそれらの製造法
JP2017155031A (ja) 2016-02-29 2017-09-07 富士フイルム株式会社 液状医薬製剤

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4675189A (en) 1980-11-18 1987-06-23 Syntex (U.S.A.) Inc. Microencapsulation of water soluble active polypeptides
JPS60100516A (ja) 1983-11-04 1985-06-04 Takeda Chem Ind Ltd 徐放型マイクロカプセルの製造法
CA1256638A (en) 1984-07-06 1989-06-27 Motoaki Tanaka Polymer and its production
JP2551756B2 (ja) 1985-05-07 1996-11-06 武田薬品工業株式会社 ポリオキシカルボン酸エステルおよびその製造法
DK0841344T3 (da) * 1996-04-09 2002-12-23 Yamasa Corp 1-(2-Desoxy-2-fluor-4-thio-Beta-D-arabinofuranosyl)cytosiner
ES2565929T3 (es) * 2004-10-25 2016-04-07 Dekk-Tec, Inc. Sales de mostaza de isofosforamida y análogos de las mismas como agentes antitumorales
US7700567B2 (en) * 2005-09-29 2010-04-20 Supergen, Inc. Oligonucleotide analogues incorporating 5-aza-cytosine therein
CN103626765B (zh) * 2012-08-27 2016-08-10 广东东阳光药业有限公司 取代的氮杂吲哚化合物及其盐、组合物和用途
WO2015125781A1 (ja) 2014-02-18 2015-08-27 富士フイルム株式会社 チオラン骨格型糖化合物の製造方法およびチオラン骨格型糖化合物
JP7425734B2 (ja) 2018-02-01 2024-01-31 ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ ２’－デオキシヌクレオシドを製造するための立体選択的合成およびプロセス
JP7520822B2 (ja) * 2018-09-25 2024-07-23 ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ ２’－ハロゲン化－４’－チオ－２’－デオキシ－５－アザシチジンアナログおよびその使用

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008523079A (ja) 2004-12-10 2008-07-03 スーパージェン インコーポレイテッド シチジンアナログ及びシチジン誘導体の医薬配合物
WO2011074484A1 (en) 2009-12-18 2011-06-23 Libramedicina, Inc. PROCESS FOR PREPARING SUBSTITUTED 1-O-ACYL-2-DEOXY-2-FLUORO-4-THIO-β-D-ARABINOFURANOSES
WO2013146833A1 (ja) 2012-03-28 2013-10-03 富士フイルム株式会社 １－（２－デオキシ－２－フルオロ－４－チオ－β－Ｄ－アラビノフラノシル）シトシンの塩
WO2014027658A1 (ja) 2012-08-13 2014-02-20 富士フイルム株式会社 １－（２－デオキシ－２－フルオロ－４－チオ－β－Ｄ－アラビノフラノシル）シトシンの合成中間体およびチオヌクレオシドの合成中間体ならびにそれらの製造法
JP2017155031A (ja) 2016-02-29 2017-09-07 富士フイルム株式会社 液状医薬製剤

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Cancer Chemother. Pharmacol.，2014年，74，291-302
Nucleosides, Nucleotides & Nucleic Acids，2003年，22，2161-2170
Pharmaceuticals，2017年，10，65(1-14)

Also Published As

Publication number Publication date
EP3856754A1 (en) 2021-08-04
JP2022502378A (ja) 2022-01-11
US20220033387A1 (en) 2022-02-03
AU2019349424B2 (en) 2024-04-04
CA3110224A1 (en) 2020-04-02
US11254662B2 (en) 2022-02-22
CN112888698A (zh) 2021-06-01
WO2020068657A8 (en) 2021-03-18
AU2019349424A1 (en) 2021-03-18
US20210292310A1 (en) 2021-09-23
WO2020068657A1 (en) 2020-04-02

Similar Documents

Publication Publication Date Title
CN101068825B (zh) 具有a2a激动剂活性的具有修饰的5＇-核糖基团的2-丙炔基腺苷类似物
US11254662B2 (en) 2′-halogenated-4′-thio-2′-deoxy-5-azacytidine analogs and use thereof
JP6936498B2 (ja) 抗アポトーシス性Ｂｃｌ−２ファミリータンパク質の分解を誘導する化合物及びその使用
US20070197565A1 (en) Bicycloheteroaryl compounds as P2X7 modulators and uses thereof
CN101128440A (zh) 作为mTOR抑制剂的肼基甲基、亚肼基甲基和5元杂环化合物及其用作抗癌剂的应用
US20100184802A1 (en) Bicycloheteroaryl Compounds as P2X7 Modulators and Uses Thereof
BR112013001553A2 (pt) Métodos e compostos para tratar infecções por vírus paramyxoviridae
CA2819560A1 (en) Treatment of jak2-mediated conditions
EA031716B1 (ru) Дейтерированный барицитиниб
EA032639B1 (ru) Гидрохлоридные соли n-(цианометил)-4-(2-(4-морфолинофениламино)пиримидин-4-ил)бензамида
JP6615207B2 (ja) 複素環式化合物及びその使用
JP2016538281A (ja) 血液脳関門を通過するタンパク質ホスファターゼ阻害剤
JP2020509014A (ja) １−（４−｛［６−アミノ−５−（４−フェノキシ−フェニル）−ピリミジン−４−イルアミノ］−メチル｝−ピペリジン−１−イル）−プロペノンの新規結晶形態
EA023104B1 (ru) Аналоги эпоксиэйкозатриеновой кислоты и способы их получения и использования
BRPI0908675B1 (pt) Composto e composição farmacêutica
US6372719B1 (en) ανβ3 integrin antagonists in combination with chemotherapeutic agents
WO2023133472A1 (en) Mek immune oncology inhibitors and therapeutic uses thereof
EP0373663B1 (en) Castanospermine esters in the inhibition of tumor metastasis
JP2008516989A (ja) 組成物及び抗腫瘍剤としてのその使用
JP2020518649A5 (https=)
JP6952911B2 (ja) ２−（αヒドロキシペンチル）安息香酸の有機アミンエステル誘導体薬物
KR20210013081A (ko) 나프록센 및 프레가발린의 1-(아실옥시)-알킬 카르바메이트 약물 복합체의 결정형
WO2020249120A1 (zh) 氨基硫醇类化合物作为脑神经或心脏保护剂的用途
JP2010520236A (ja) リソフィリンアナログとその使用法
CN105143197A (zh) 新的晶体形式

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220831

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220831

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230906

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231205

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240205

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240501

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240703

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240710

R150 Certificate of patent or registration of utility model

Ref document number: 7520822

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150